Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer's Disease: An Observational Study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
We previously reported that angiotensin converting enzyme inhibitors (ACEIs) decrease the rate of cognitive decline in elderly patients with hypertension, but their impact on patients with Alzheimer's disease (AD) is not known. A total of 62 elderly patients with AD were enrolled, and 52 completed the study for 6 months. Mini-Mental Status Examination (MMSE), Clock Draw Test (CDT), working memory (Digit Ordering), Instrumental Activities of Daily Living (IADL) scale, and the Screen for Caregiver Burden (SCB) were collected at baseline, 3 months, and 6 months. AD patients receiving ACEI (N = 15) demonstrated a slower rate of decline in digit forward ( P = .003) and IADL scale ( P = .003) and an improved measure of caregiver burden ( P = .04) but not MMSE ( P =.15) or CDT ( P =.9) compared with those not receiving ACEI after adjusting for other risk factors. This study suggests that use of ACEI in AD patients is associated with slower rate of AD progression. A randomized clinical trial is needed to confirm our finding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Staessen, J. A. (1999) · JAMA · doi:10.1001/jama.282.6.539 · Cited by 1,592
Knopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410 · cited 1×
“The inclusion criteria were the following: (1) age 55 years or older, (2) available caregiver or guardian to provide informed consent and study information on participants’ cognitive and functional status, (3) ability to perform the study procedures and to present to the study center, and (4) a diagnosis of probable o…”
Midlife cardiovascular risk factors and risk of dementia in late life
Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C., & Yaffe, K. (2005) · Neurology · doi:10.1212/01.wnl.0000149519.47454.f2 · Cited by 1,238
Social Disengagement and Incident Cognitive Decline in Community-Dwelling Elderly Persons
Bassuk, S. S., Glass, T. A., & Berkman, L. F. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00002 · Cited by 991
Dufouil, C., Chalmers, J., Coskun, O., Besançon, V., Bousser, M.-G., Guillon, P., MacMahon, S., Mazoyer, B., Neal, B., Woodward, M., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.501163 · Cited by 461 · cited 2×
“ACEIs have also been shown to decrease the progression of white matter hyperintensities, which has been linked to further cognitive and functional declines.(14)A prior in vitro study has suggested that ACE may decrease levels of Aβ protein.”
BackgroundLehmann, D. J., Cortina-Borja, M., Warden, D. R., Smith, A. D., Sleegers, K., Prince, J. A., van Duijn, C. M., & Kehoe, P. G. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi202 · Cited by 199 · cited 9×
“In addition, a recent observational study in the United Kingdom showed a protective effect of ACEI on the global deterioration scale in patients with AD.38 Prior studies have suggested a U-shaped association between blood pressure and cognitive function.39 In this study, our association between ACEI and outcomes remai…”
BackgroundInfluentialEckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 1×
“More recently, in vivo animal studies failed to show a role of ACE in Aβ protein.(37) Our study also suggests that ACEIs do not show a detrimental effect on AD progression.”
BackgroundRozzini, L., Chilovi, B. V., Bertoletti, E., Conti, M., Rio, I. D., Trabucchi, M., & Padovani, A. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1523 · Cited by 93 · cited 1×
“This is further corroborated by a recent study in patients with amnestic mild cognitive impairment, where those receiving ACEI showed a lower risk for further cognitive decline.(16) If similar protective effects can be demonstrated in AD patients, then new therapeutic options for this debilitating condition may be ava…”
Result
Cited by
Salkovic-Petrisic, M., Knezovic, A., Hoyer, S., & Riederer, P. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0877-9 · Cited by 272
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
Lupus antibodies induce behavioral changes mediated by microglia and blocked by ACE inhibitors
Nestor, J., Arinuma, Y., Huerta, T. S., Kowal, C., Nasiri, E., Kello, N., Fujieda, Y., Bialas, A., Hammond, T., Sriram, U., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180776 · Cited by 146
“ACE inhibitors block neurotoxic DNRAbs 2559 servational studies in AD patients also suggest benefit from ACE inhibition (Hajjar et al., 2008; Soto et al., 2013; Yasar et al., 2013; de Oliveira et al., 2014, 2018; O’Caoimh et al., 2014; Zhuang et al., 2016).”
BackgroundKehoe, P. G. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171119 · Cited by 133
Sequence Variants of Toll Like Receptor 4 and Late-Onset Alzheimer's Disease
Chen, Y.-C., Yip, P.-K., Huang, Y.-L., Sun, Y., Wen, L.-L., Chu, Y.-M., & Chen, T.-F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050771 · Cited by 38
“, reduce neuronal damage and slow progression of AD [41,42].”
Background
Metadata
- Authors
- Hajjar, I. M., Keown, M., Lewis, P., & Almor, A.
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2008-02
- Volume
- 23
- Issue
- 1
- Pages
- 77-83
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- OpenAlex
- W2153958083
- Cited by
- 53
- References
- 11
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer's Disease: An Observational Study. https://app.cochat.ai/papers/10.1177/1533317507309803
- The paper
- Hajjar, I. M., Keown, M., Lewis, P., & Almor, A. (2008). Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer's Disease: An Observational Study. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317507309803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.